register

News & Trends - Pharmaceuticals

Ovarian Cancer Australia to make PBAC submission in support of GSK’s PARP inhibitor

Health Industry Hub | January 20, 2021 |

Pharma News: GSK’s PARP inhibitor for ovarian cancer patients was approved by the Therapeutic Goods Administration (TGA) in June 2019 and is still awaiting the Pharmaceutical Benefits Advisory Committee (PBAC) approval.

Ovarian Cancer Australia is advocating for the reimbursement of Zejula (niraparib) by making a submission to the Pharmaceutical Benefits Scheme (PBS).

A GSK Australia spokesperson told Health Industry Hub “When reimbursed, Zejula will be the first PARP inhibitor to be listed on the PBS for the maintenance treatment of women with platinum sensitive recurrent ovarian cancer, regardless of BRCA mutation status, which occurs in only ~30% of women.

“It is estimated ovarian cancer will be the 10th most commonly diagnosed cancer among females in Australia, yet it has one of the poorest 5-year relative survival rates at 45.7%. It is estimated that almost 1,500 new cases of ovarian cancer have been diagnosed in Australia in 2020.

“There remains a high unmet need for women with ovarian cancer beyond BRCA mutation status. We are therefore hopeful the PBAC will see the contribution Zejula can bring to women living with advanced ovarian cancer who need additional options earlier in their treatment pathway.”

Ovarian Cancer Australia (OCA) is asking consumers to have their say directly or via the OCA survey.

GSK confirmed the company’s commitment to bringing Zejula to Australian patients as quickly as possible and looks forward to working with the PBAC to ensure this therapy is publicly funded in a timely manner.


News & Trends - Pharmaceuticals

Is the government is gearing up to release the long-awaited response to The New Frontier report?

Government’s long-awaited response to The New Frontier report unveiled after two-year wait

Health Industry Hub | December 1, 2023 |

Pharma News: The Albanese Government has tabled its response to the House of Reps inquiry and The New Frontier report […]

More


News & Trends - Pharmaceuticals

Gilead welcomes HIV Taskforce report and celebrates the 'unsung heroes'

Gilead welcomes HIV Taskforce report and celebrates the ‘unsung heroes’

Health Industry Hub | December 1, 2023 |

Pharma News: On World AIDS Day, the National Association of People with HIV Australia (NAPWHA) and Gilead Sciences Australia have […]

More


News & Trends - Pharmaceuticals

AbbVie secures PBS listing of first therapy for Crohn's disease in seven years

AbbVie secures PBS listing of first therapy for Crohn’s disease in seven years

Health Industry Hub | December 1, 2023 |

Pharma News: AbbVie’s Rinvoq (upadacitinib), a once-daily tablet, has been officially listed on the Pharmaceutical Benefits Scheme (PBS) for adult […]

More


ESG

New report calls on policy integration of sustainability in medical device and pharmaceutical registrations and funding

New report calls on policy integration of sustainability in medical device and pharmaceutical registrations and funding

Health Industry Hub | November 30, 2023 |

ESG: Increasing pressures from diverse stakeholder groups, spanning policymakers, investors, customers, and employees, have elevated Environmental, Social, and Governance (ESG) […]

More


This content is copyright protected. Please subscribe to gain access.